Humor and Quirks Humor and Quirks
Wed, December 11, 2024
Tue, December 10, 2024
[ Tue, Dec 10th 2024 ] - The New Yorker
The Dawn of the Bionic Man
[ Tue, Dec 10th 2024 ] - Mercury News
California News
[ Tue, Dec 10th 2024 ] - ABC News
Entertainment News
Mon, December 9, 2024
[ Mon, Dec 09th 2024 ] - BBC
Beds, Herts & Bucks
[ Mon, Dec 09th 2024 ] - Uproxx
The Best TV Shows Of 2024
[ Mon, Dec 09th 2024 ] - Paste
The 25 Best PC Games of 2024
[ Mon, Dec 09th 2024 ] - CNET
Top News Stories
Sun, December 8, 2024
Sat, December 7, 2024
[ Sat, Dec 07th 2024 ] - Newsweek
Russia-Ukraine War
[ Sat, Dec 07th 2024 ] - imdb.com
Canada's 30 Funniest TV Shows
[ Sat, Dec 07th 2024 ] - Daily Mail
UK Celebrity News
[ Sat, Dec 07th 2024 ] - Food Safety News
Food Safety News
Fri, December 6, 2024
[ Fri, Dec 06th 2024 ] - Graphic
Latest Ghana News Headlines Today
[ Fri, Dec 06th 2024 ] - The Columbian
Clark County News
[ Fri, Dec 06th 2024 ] - who13
Cyclones react to 10 wins
[ Fri, Dec 06th 2024 ] - TravelPulse
Hotels and Resorts News
[ Fri, Dec 06th 2024 ] - Business Standard
Share Market Today
[ Fri, Dec 06th 2024 ] - Reuters
Aerospace & Defense
Thu, December 5, 2024
[ Thu, Dec 05th 2024 ] - Interest
All news stories
[ Thu, Dec 05th 2024 ] - Stereogum
When Comedians Make Serious Music
[ Thu, Dec 05th 2024 ] - Paste
The 30 Best TV Shows of 2024
[ Thu, Dec 05th 2024 ] - Phil Bruner
Featured News Stories
[ Thu, Dec 05th 2024 ] - Phil Bruner
Swattie Survival Guide
Wed, December 4, 2024
[ Wed, Dec 04th 2024 ] - Phil Bruner
California News
[ Wed, Dec 04th 2024 ] - Phil Bruner
President Joe Biden
Tue, December 3, 2024
[ Tue, Dec 03rd 2024 ] - Phil Bruner
The 40 Best Games of 2024
[ Tue, Dec 03rd 2024 ] - Phil Bruner
Boku No Roblox Codes
[ Tue, Dec 03rd 2024 ] - Phil Bruner
Yonhap News Agency
[ Tue, Dec 03rd 2024 ] - Phil Bruner
Beds, Herts & Bucks
[ Tue, Dec 03rd 2024 ] - Phil Bruner
Transfer news and rumors
Mon, December 2, 2024
[ Mon, Dec 02nd 2024 ] - Phil Bruner
Watch Samaa News Live
[ Mon, Dec 02nd 2024 ] - Phil Bruner
UK Celebrity News
[ Mon, Dec 02nd 2024 ] - Phil Bruner
The 100 Best Albums of 2024
[ Mon, Dec 02nd 2024 ] - Phil Bruner
From the Newspaper
[ Mon, Dec 02nd 2024 ] - Phil Bruner
South Australia
[ Mon, Dec 02nd 2024 ] - Phil Bruner
Whanganui Chronicle
Sun, December 1, 2024
[ Sun, Dec 01st 2024 ] - Phil Bruner
Wildlife Oddities of the Week
Sat, November 30, 2024
Fri, November 29, 2024
[ Fri, Nov 29th 2024 ] - Phil Bruner
Hotels and Resorts News
[ Fri, Nov 29th 2024 ] - Phil Bruner
The Best Jokes of 2024
Thu, November 28, 2024
[ Thu, Nov 28th 2024 ] - Phil Bruner
Climate and Environment
[ Thu, Nov 28th 2024 ] - Phil Bruner
December 2024 Issue
Wed, November 27, 2024
[ Wed, Nov 27th 2024 ] - Phil Bruner
Decoding Gen Z's content diet
Tue, November 26, 2024
[ Tue, Nov 26th 2024 ] - Phil Bruner
Illustrated Humor in the News
[ Tue, Nov 26th 2024 ] - Phil Bruner
World News
[ Tue, Nov 26th 2024 ] - Phil Bruner
Alexandra Petri
Mon, November 25, 2024
[ Mon, Nov 25th 2024 ] - Phil Bruner
Legal IT's Leading News Source
[ Mon, Nov 25th 2024 ] - Phil Bruner
All Kent news
Sun, November 24, 2024
Mon, December 15, 2008
[ Mon, Dec 15th 2008 ] - Market Wire
fasdfasddva s gfg h

Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Peregrine Pharmaceuticals, Inc.


//health-fitness.news-articles.net/content/2010/ .. ew-r-eio-r-on-peregrine-pharmaceuticals-inc.html
Published in Health and Fitness on Monday, May 17th 2010 at 5:41 GMT by Market Wire   Print publication without navigation


NEW YORK, NY--(Marketwire - May 17, 2010) - Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview® (EIO®) on Peregrine Pharmaceuticals, Inc. (NASDAQ: [ PPHM ]). The full 80-page report can be found at [ www.crystalra.com ].

Peregrine Pharmaceuticals, Inc. ("Peregrine" or "the Company") is a clinical-stage biopharmaceutical company focused on the development of monoclonal antibody (MAb)-based therapeutics for oncology and viral diseases. Peregrine's proprietary MAbs have demonstrated broad-spectrum potential in cancer and viral disease and target a range of diseased cells, including cells lining the blood vessels that feed tumors, cells that have been infected with an enveloped virus, and the dead or dying cells (necrosis) found at the core of solid tumors.

Peregrine is advancing its clinical programs for bavituximab, a phosphatidylserine (PS)-targeting MAb to treat certain cancers and viral infections, and Cotara®, a novel brain cancer therapy. Bavituximab, in combination with chemotherapy, is in a Phase II trial for non-small cell lung cancer (NSCLC) and two Phase II trials for advanced breast cancer. Bavituximab is also in a Phase I trial in patients co-infected with hepatitis C virus (HCV) and HIV. Cotara is in a Phase II study in patients with relapsed glioblastoma multiforme (GBM), an aggressive and often fatal brain cancer. This trial has recently been expanded to include U.S. sites.

Peregrine has two sources of revenue: (1) its subsidiary Avid Bioservices®, Inc., which provides commercial biomanufacturing services for both Peregrine and outside customers; and (2) a government contract valued at up to $44 million for five years.

About Crystal Research Associates, LLC

Crystal Research Associates, LLC is an independent research firm that provides institutional-quality, fee-based research to small- and mid-cap companies. Crystal Research Associates' unique and novel product, the Executive Informational Overview® (EIO®), is free of investment ratings, target prices, and forward-looking financial models. The EIO® presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO® details a company's product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, financial statements, key events, and other such fundamental information. Crystal Research Associates has offices in New York City, West Palm Beach, Montréal, and Toronto. Crystal Research Associates has been compensated by the Company in cash of fifty-four thousand dollars for its services in creating this report, for updates, and for printing costs.

Forward-Looking Safe Harbor Statement

Statements in this news release regarding future financial and operating results, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements including, limited operating history, need for future capital, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including forms filed with the SEC.

These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates assumes no obligation to update any of the forward-looking statements in this release.


Publication Contributing Sources